Abstract
The coronavirus disease 2019 (COVID-19) pandemic affected the entire world with unprecedented impact on the health care and economy of countries. India, the most populous country, faced enormous challenges across its diverse population groups. The end-stage renal disease (ESRD) patients on dialysis, especially hemodialysis, were a high-risk group with inevitable regular hospital visits in contrast to the home peritoneal dialysis group. The unplanned lockdown and home confinement posed many risks to dialysis patients due to dialysis unit closures, logistical issues, and severe COVID-19-related morbidities. We have paucity of data on mortality of dialysis patients in India. We describe the reported and available data on COVID-19 in India from across different centers. The vaccination provided by two different pharmaceuticals such as Covaxin and Covishield in a small cohort of dialysis patients reduced infection and severity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
